Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.33 USD | +0.10% | -3.28% | +27.06% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.06% | 2.89B | D+ | ||
-27.70% | 9.87B | A- | ||
-16.78% | 2.75B | C | ||
-15.31% | 2.13B | - | B- | |
-21.41% | 1.65B | C+ | ||
+68.70% | 1.47B | B- | ||
+29.75% | 811M | C- | ||
-5.02% | 733M | C+ | ||
-29.39% | 510M | C- | ||
+1.59% | 300M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IOVA Stock
- Ratings Iovance Biotherapeutics, Inc.